Arg206
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Methylation Site Page: > Arg206  -  AML1 (human)

Site Information
sELEQLRrtAMrVsP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2363103

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
leukemia ( 1 ) , acute myelogenous leukemia ( 1 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 1 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 1 ) , chronic myelogenous leukemia ( 1 )
Relevant cell line - cell type - tissue:
erythroid ( 1 ) , HEL (erythroid) ( 1 ) , HeLa (cervical) ( 1 ) , Kasumi-1 (myeloid) ( 1 ) , Meg01 (megakaryoblast) ( 1 ) , megakaryocyte ( 1 ) , myeloid ( 1 )

Upstream Regulation
Treatments:
5'-methylthioadenosine ( 1 ) , siRNA ( 1 )

Downstream Regulation
Effects of modification on AML1:
molecular association, regulation ( 1 )
Effects of modification on biological processes:
cell differentiation, altered ( 1 ) , transcription, induced ( 1 )
Inhibit interaction with:
DNA ( 1 ) , SIN3A (human) ( 1 )

References 

1

Zhao X, et al. (2008) Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev 22, 640-53
18316480   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.